FOSTER CITY (dpa-AFX) - Friday, Gilead Sciences, Inc. (GILD) announced the
successful acquisition of CymaBay Therapeutics, Inc. (CBAY) for around $4.3
billion.

This acquisition involved a tender offer where the majority of CymaBay's shares
were bought at $32.50 each.

Following the merger, CymaBay now operates as a fully owned subsidiary of
Gilead, and CymaBay's common stock is no longer available for trading on the
Nasdaq.

The acquisition is expected to strengthen Gilead's market position by broadening
its portfolio with CymaBay's promising investigational lead product candidate,
Seladelpar, targeted for treating primary biliary cholangitis and pruritus.

This transaction is projected to impact Gilead's GAAP and non-GAAP 2024 earnings
per share by approximately $3.10 - $3.20.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX